

Lazertinib (LAZCLUZE)

Criteria for Use

May 2026

VA Pharmacy Benefits Management Services and National Formulary Committee

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

Exclusion Criteria

If ANY of the following are selected, the patient will NOT meet criteria for lazertinib.

- Active or untreated brain metastases
- Pregnancy
- Lactating

Inclusion Criteria

ALL of the following must be selected to meet criteria.

- In combination with amivantamab for first-line therapy of locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R substitution mutations[^]

[^]Anticoagulation to prevent VTE during first 4 months of combination therapy. Dermatologic prophylaxis: oral antibiotics for first 12 weeks followed by topical clindamycin, chlorhexidine wash daily, moisturizer, and sunscreen as per package insert.

Additional Inclusion Criteria

All of the following criteria must be selected to meet criteria.

- Care is provided by a VA/VA Community Care oncology provider
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Goals of care and role of Palliative Care consult have been discussed and documented

Additional Inclusion Criteria – Select If Applicable

- For females who can become pregnant and males with female partners who can become pregnant: Counseling on treatment risks vs benefits and use of effective contraception during and for 3 months after last treatment of lazertinib plus amivantamab.

Other Justification

- _____

Original: May 2026

Contact: Mark C. Geraci, Pharm.D., BCOP, National Program Manager, VA Pharmacy Benefits Management Services – Formulary Management (12PBM)